Is Wall Street Bullish or Bearish on Incyte Stock?

Wilmington, Delaware-based Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for serious medical needs. Valued at a market cap of $12.3 billion, the company's primary focus areas include oncology, inflammation, and autoimmunity. 

This biotech company has underperformed the broader market over the past 52 weeks. Shares of INCY have gained 11.3% over this time frame, while the broader S&P 500 Index ($SPX) has soared 12.5%. Moreover, on a YTD basis, the stock is down 8.3%, compared to SPX’s 1.3% uptick.